Back
Adaptive Biotechnologies 10K Form
Buy
52
ADPT
Adaptive Biotechnologies
Last Price:
3.60
Seasonality Move:
11.74%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-09 | 10Q | ADPT/Adaptive Biotechnologies Quarterly |
| 2023-08-02 | 10Q | ADPT/Adaptive Biotechnologies Quarterly |
| 2023-05-03 | 10Q | ADPT/Adaptive Biotechnologies Quarterly |
| 2022-11-03 | 10Q | ADPT/Adaptive Biotechnologies Quarterly |
| 2022-08-03 | 10Q | ADPT/Adaptive Biotechnologies Quarterly |
| 2022-05-04 | 10Q | ADPT/Adaptive Biotechnologies Quarterly |
Receive ADPT News And Ratings
See the #1 stock for the next 7 days that we like better than ADPT
ADPT Financial Statistics
Sales & Book Value
| Annual Sales: | $170.28M |
|---|---|
| Cash Flow: | $-39.86M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.87 |
| Price / Book: | 1.94 |
Profitability
| EPS (TTM): | -1.49000 |
|---|---|
| Net Income (TTM): | $-215.06M |
| Gross Margin: | $94.72M |
| Return on Equity: | -60.94% |
| Return on Assets: | -30.25% |
Adaptive Biotechnologies Earnings Forecast
Key Adaptive Biotechnologies Financial Ratios
- The Gross Profit Margin over the past 18 years for ADPT is 55.63%.
- The Selling, General & Administrative Expenses for ADPT have been equal to 101.31% of Gross Profit Margin.
- The Research & Development expenses have been 71.72% of Revenue.
- The Interest Expense is -6.13% of Operating Income.
- The Net Earning history of ADPT is -132.29% of Total Revenues.
- Per Share Earnings over the last 18 years have been positive in 5 years.
Adaptive Biotechnologies Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Life Sciences Tools & Services |
| Sector: | Health Care |
| Current Symbol: | ADPT |
| CUSIP: | 00650F |
| Website: | adaptivebiotech.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 4.51 |
| Quick Ratio: | 4.23 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ADPT Technical Analysis vs Fundamental Analysis
Buy
52
Adaptive Biotechnologies (ADPT)
is a Buy
Is Adaptive Biotechnologies a Buy or a Sell?
-
Adaptive Biotechnologies stock is rated a Buy
The current Adaptive Biotechnologies [ADPT] share price is $3.61. The Score for ADPT is 52, which is 4% above its historic median score of 50, and infers lower risk than normal.